Shanghai Jiao Tong University School of Medicine Tests Intranasal Umbilical Cord Exosomes for Early Parkinson’s Disease

A single-center Phase 1/2 dose-escalation study will assess whether intranasal exosomes from umbilical cord mesenchymal stromal cells are safe and tolerable, and whether they may improve motor and non-motor symptoms and imaging measures in adults with early Parkinson’s disease over 48 weeks.

Shanghai Jiao Tong University School of Medicine is sponsoring a Phase 1/2 trial to evaluate an intranasal spray of exosomes derived from umbilical cord mesenchymal stromal cells in adults with early Parkinson’s disease. The product, called UCMSC-Exo, is a cell-free liquid containing exosomes in saline and is given by nasal spray rather than intravenously.

The single-center, open-label, dose-escalation study uses a 3+3 design with no placebo and no blinding. Nine participants are already enrolled. Researchers are assessing whether the intranasal exosomes are safe and tolerable at escalating concentrations, and whether they may improve motor and non-motor symptoms, biomarkers, and imaging measures over a 48-week follow-up period.

  • Sponsor: Shanghai Jiao Tong University School of Medicine, China
  • Phase/Status: Phase 1, Phase 2; Active not recruiting
  • Indication: Early Parkinson’s disease in adults aged 50–75; actual enrollment of 9 participants
  • Arms/Dosing: Low-dose intranasal UCMSC-Exo: 5×10^8 particles/mL, 0.4 mL total (200 µL/nostril; 2 sprays/nostril), twice weekly for 12 weeks. Medium-dose intranasal UCMSC-Exo: 1×10^9 particles/mL, same volume and schedule. High-dose intranasal UCMSC-Exo: 2×10^9 particles/mL, same volume and schedule. All doses given with usual dopaminergic therapy continued.
  • Control: None
  • Endpoints: Primary: incidence, severity, and relationship to study intervention of local and systemic adverse events and serious adverse events from first dose through Week 48, assessed at Weeks 4, 12, 16, and 48. Other planned assessments: changes in motor and non-motor symptoms, biomarkers, and imaging measures at Weeks 12, 16, 24, 36, and 48.
  • Timing: Study start: October 28, 2024 (actual). Estimated primary completion: June 30, 2027. Estimated study completion: June 30, 2027.

NCT07923838

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories